Alnylam To Report New Clinical Results With Investigational RNAi Therapeutics For The Treatment Of Transthyretin-Mediated Amyloidosis At The First European Congress On Hereditary ATTR Amyloidosis

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that Alnylam scientists and collaborators will present results from ongoing Phase 2 open-label extension (OLE) studies with its investigational RNAi therapeutics in development for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR amyloidosis) at the First European Congress on Hereditary ATTR Amyloidosis being held November 2-3, 2015 in Paris, France. The presentations will include 18-month patisiran data for the treatment of patients with Familial Amyloidotic Polyneuropathy (FAP) and 6-month revusiran data for the treatment of patients with TTR cardiac amyloidosis, including Familial Amyloidotic Cardiomyopathy (FAC) and Senile Systemic Amyloidosis (SSA), a non-hereditary form of TTR cardiac amyloidosis. The Company will host a conference call on Tuesday, November 3 at 7:00 a.m. ET to discuss these results.

Help employers find you! Check out all the jobs and post your resume.